Connor, Clark & Lunn Investment Management (CC&L)
PBYI icon

Connor, Clark & Lunn Investment Management (CC&L)’s Puma Biotechnology PBYI Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.21M Sell
642,946
-139,852
-18% -$1.02M 0.01% 715
2026
Q1 		$5M Sell
782,798
-92,503
-11% -$596K 0.01% 685
2025
Q4 		$5.21M Sell
875,301
-68,171
-7% -$362K 0.01% 634
2025
Q3 		$5.01M Buy
943,472
+43,216
+5% +$183K 0.02% 578
2025
Q2 		$3.09M Buy
900,256
+68,567
+8% +$219K 0.01% 725
2025
Q1 		$2.46M Buy
831,689
+344,321
+71% +$1.08M 0.01% 676
2024
Q4 		$1.49M Buy
487,368
+118,913
+32% +$346K 0.01% 809
2024
Q3 		$940K Buy
368,455
+13,941
+4% +$42.2K ﹤0.01% 903
2024
Q2 		$1.16M Sell
354,514
-31,349
-8% -$138K ﹤0.01% 815
2024
Q1 		$2.05M Buy
385,863
+189,204
+96% +$1.02M 0.01% 666
2023
Q4 		$852K Sell
196,659
-3,108
-2% -$10.3K ﹤0.01% 904
2023
Q3 		$525K Hold
199,767
– – ﹤0.01% 1001
2023
Q2 		$705K Buy
199,767
+15,822
+9% +$49.4K ﹤0.01% 893
2023
Q1 		$568K Buy
183,945
+675
+0.4% +$2.54K ﹤0.01% 848
2022
Q4 		$775K Buy
183,270
+33,976
+23% +$117K ﹤0.01% 770
2022
Q3 		$354K Buy
149,294
+71,703
+92% +$209K ﹤0.01% 882
2022
Q2 		$221K Sell
77,591
-13,140
-14% -$32.7K ﹤0.01% 912
2022
Q1 		$261K Sell
90,731
-9,484
-9% -$24.5K ﹤0.01% 901
2021
Q4 		$305K Buy
+100,215
New +$435K ﹤0.01% 892
2020
Q2 		– Sell
-11,467
Closed -$97K – 1143
2020
Q1 		$97K Buy
+11,467
New +$111K ﹤0.01% 936
2016
Q4 		– Sell
-3,925
Closed -$263K – 960
2016
Q3 		$263K Sell
3,925
-22,800
-85% -$1.15M ﹤0.01% 696
2016
Q2 		$796K Sell
26,725
-525
-2% -$16.4K 0.01% 505
2016
Q1 		$800K Sell
27,250
-2,100
-7% -$94.9K 0.01% 494
2015
Q4 		$2.3M Sell
29,350
-6,525
-18% -$512K 0.02% 309
2015
Q3 		$2.7M Buy
35,875
+275
+0.8% +$26K 0.02% 262
2015
Q2 		$4.16M Buy
35,600
+600
+2% +$109K 0.04% 169
2015
Q1 		$8.26M Buy
35,000
+14,100
+67% +$3.01M 0.07% 129
2014
Q4 		$3.96M Buy
20,900
+12,300
+143% +$2.73M 0.03% 175
2014
Q3 		$2.05M Buy
+8,600
New +$1.77M 0.02% 214

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PBYI Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Puma Biotechnology (PBYI) stake by 18% in Q2 2026, selling an estimated $1.02M and leaving 642,946 shares worth $5.21M. The position accounts for 0.01% of the portfolio, ranked #715.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PBYI in Q3 2014 and has held it in 29 quarters since. The position peaked at $8.26M in Q1 2015. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 642,946 shares of Puma Biotechnology worth $5.21M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 139,852 Puma Biotechnology shares in Q2 2026, an estimated $1.02M.
  • Puma Biotechnology made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #715 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Puma Biotechnology in Q3 2014 and has held it in 29 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Puma Biotechnology position peaked at $8.26M in Q1 2015.
  • 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.